What is the difference between the blast phase and the cruise phase in a trenbolone cycle?

The blast phase is a defined period of elevated androgen dosing — typically 8–16 weeks — where trenbolone acetate is added to drive maximal muscle adaptation. The cruise phase that follows uses testosterone-only maintenance dosing, commonly 100–200mg per week, for 4–12 weeks. This alternation allows partial hormonal recovery and helps preserve long-term androgen receptor responsiveness across successive training years.

How does trenbolone acetate's clearance rate affect the blast-to-cruise transition?

Trenbolone acetate clears serum meaningfully faster than long-ester variants, with detectable activity dropping sharply within approximately one week of the final injection. This means athletes can transition cleanly into the cruise phase without waiting weeks for residual hormone levels to subside — a practical advantage for anyone timing blood panels or managing total androgen load during the handoff between phases.

How many weeks should the blast phase last when using NordiTren A?

Most experienced practitioners run blast phases of 8–12 weeks when trenbolone acetate is the primary anabolic compound. Shorter blasts of 6 weeks are sometimes used for targeted pre-competition peaks. The blast length should be determined in relation to the subsequent cruise duration — a commonly cited ratio is one week of cruise for every week blasted, though individual health markers and bloodwork should guide adjustments.

Why does the 150mg/ml concentration of NordiTren A matter for blast-phase injection scheduling?

At 150mg/ml, a 450mg weekly blast dose requires only 3ml of product across the injection schedule. An equivalent dose from a 100mg/ml product requires 4.5ml — a 50% increase in total injection volume per week. Across an 8-week blast, that difference accumulates to roughly 12ml, which translates to fewer large-volume draws and reduced injection-site stress during high-frequency dosing.

Can NordiTren A be drawn with an insulin syringe, and how should the vial be stored after first use?

Drawing from a 150mg/ml oil-based preparation with an insulin syringe is technically possible for very small doses but is generally impractical due to viscosity; a 23–25g needle is the standard recommendation for both drawing and injection. After first puncture, the vial should be stored upright at room temperature away from light and heat, used within the period indicated on the label, and the stopper should be swabbed with an alcohol wipe before each draw to maintain sterility. (2) angle_used

Advanced Formula

Nordi Pharma

NordiTren A 150mg/ml 10ml Vial by Nordi Pharma

Name: NordiTren A 150mg/ml 10ml Vial by Nordi Pharma
Brand: Nordi Pharma
SKU: INJ-TACE-NOR-150-015
Price: 50.00 EUR
Availability: InStock
Rating: 4.5 (2 reviews)

4.5 (2 reviews)

NordiTren A is a single-active-ingredient trenbolone acetate injectable, formulated at 150mg/ml in a 10ml vial, purpose-built for athletes who structure their training year around defined blast and cruise phases. The 150mg/ml concentration reduces per-injection draw volume during high-intensity blast blocks compared to standard 100mg/ml alternatives, allowing precise phase-to-phase dose transitions without volume inconvenience. Quality assurance is executed under GMP-compliant conditions; HPLC potency verification and LAL endotoxin assay results are completed per batch before release.

€50.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Delivers 150mg of trenbolone acetate per millilitre — the highest concentration in this product category, reducing total draw volume during blast phases.
Short active window supports clean phase transitions, allowing cruise periods to begin without multi-week residual trenbolone clearance delays.
HPLC-verified concentration accuracy per batch provides a confirmed milligram foundation for calculating total weekly androgen load across blast protocols.
Single active ingredient formulation eliminates compound interaction variables when stacking during multi-drug blast phases.
10ml vial format provides sufficient volume for a complete 6–8 week blast phase at moderate dosing without requiring multiple vials.
LAL endotoxin assay clearance per batch reduces injection-site inflammatory risk during high-frequency blast-phase dosing schedules.
GMP-compliant manufacturing provides consistent oil-carrier viscosity and sterility across vials, supporting predictable injection-day experience.

Phase	Dosage	Note
Cruise (testosterone only — no NordiTren A)	Testosterone 100–200mg/week	Trenbolone removed entirely; cruise length typically matches blast length; bloodwork recommended mid-cruise
Blast — Entry Level (first blast with trenbolone)	NordiTren A 300mg/week (2ml total at 150mg/ml, split across 3 injections)	Baseline blast dose; assess tolerability across weeks 1–3 before considering escalation
Blast — Intermediate	NordiTren A 450mg/week (3ml total at 150mg/ml, split across 3–6 injections)	Standard experienced-user blast dose; run for 8–12 weeks maximum
Blast — Advanced / Pre-Competition	NordiTren A 600mg/week (4ml total at 150mg/ml)	High-androgen blast; reserved for highly experienced users; cardiovascular and hepatic markers must be actively monitored
Blast Wind-Down (final 1–2 weeks of blast)	Reduce to 50% of peak blast dose	Gradual dose reduction before entering cruise allows smoother hormonal descent; leverages acetate ester's fast clearance

Key takeaways

Structure blast phases with NordiTren A at 300–450mg weekly for defined adaptation blocks.
Transition cleanly to cruise using trenbolone acetate's rapid post-blast clearance profile.
Leverage the 150mg/ml concentration to reduce weekly injection volume by up to 33%.
Verify blood panels during cruise windows to confirm hormonal recovery before the next blast.
Confirm batch-specific HPLC potency data before calculating total weekly androgen load.

NordiTren A as a Blast-Phase Anchor in Structured Hormonal Periodisation

NordiTren A (trenbolone acetate 150mg/ml) is a high-concentration injectable androgen designed specifically to serve as the central anabolic compound during the blast phase of a blast-and-cruise hormonal periodisation strategy. The blast-and-cruise model divides a training year into alternating periods: a blast phase in which total weekly androgen dose is elevated to stimulate maximal adaptive response, and a cruise phase in which dose is reduced to a maintenance level — typically testosterone only — allowing the body's hormonal milieu to partially recover before the next blast. Trenbolone acetate's rapid clearance profile makes it logistically suited to this model because blast phases can be terminated cleanly and the compound exits the system within days, leaving the cruise window uncluttered by residual trenbolone activity.

Phase Structure and Dose Architecture for Blast vs. Cruise

During a blast phase, experienced users typically incorporate NordiTren A at 300–450mg per week, delivered in frequent injections that capitalise on the compound's short active window; at 150mg/ml, a full blast dose of 450mg per week requires only 3ml of product across the injection schedule — a meaningful reduction in cumulative injection volume compared to running equivalent doses from a 100mg/ml formulation, which would require 4.5ml for the same weekly output. The cruise phase removes trenbolone entirely: the user maintains testosterone at a replacement-level dose — commonly 100–200mg per week — for a defined period of four to twelve weeks before initiating the next blast cycle. This structured alternation, confirmed by athletes and sports medicine practitioners monitoring hormone panels, allows androgen receptor sensitivity to partially reset between blast blocks, which supports sustained responsiveness across multi-year training careers.

Pharmacokinetic Fit for Cycle Transitions

Trenbolone acetate clears the system substantially faster than long-ester trenbolone variants, with detectable serum activity dropping sharply within approximately one week of the last injection. This accelerated clearance means the transition from blast to cruise is not delayed by weeks of residual hormone activity — a practical advantage over enanthate or hexahydrobenzylcarbonate esters when managing the timing of cruise-phase blood panels. Nordi Pharma's HPLC-verified concentration accuracy ensures that each injection delivers a confirmed milligram dose, which matters directly in blast-phase planning where the athlete is managing total weekly androgen load across multiple compounds simultaneously.

Manufacturing Standard Relevant to Multi-Compound Protocols

Nordi Pharma subjects each NordiTren A batch to a dual-verification release process: HPLC identity and potency data confirm the declared 150mg/ml concentration, and LAL endotoxin assay results confirm the bacterial endotoxin load falls within pharmacopoeial acceptance limits before the batch is approved for distribution. GMP-compliant manufacturing conditions underpin both checkpoints.

Usage

Plan your blast and cruise calendar before the first injection: define blast length (8–12 weeks), target cruise length, and the bloodwork dates during cruise — this architecture determines injection frequency and total vial consumption from NordiTren A.
At the start of the blast phase, confirm the intended weekly dose in milligrams and calculate draw volume using the 150mg/ml concentration (e.g., 450mg/week = 3ml/week total) to establish your per-injection draw volume across the weekly schedule.
Inject using a 23–25g needle into large muscle groups (glute, vastus lateralis); swab the vial stopper with an alcohol wipe before each draw and allow the oil to reach room temperature for improved flow if storage conditions have cooled the vial.
During the blast phase, maintain consistent injection timing to minimise peak-to-trough hormone variability; at 150mg/ml a three-times-weekly schedule is common, but daily or EOD schedules are used by athletes prioritising hormonal flatness.
At blast termination, do not simply stop abruptly — reduce the dose across the final one to two weeks of the blast before switching fully to the cruise protocol; the acetate ester's rapid clearance supports a fast hormonal descent once administration ends.
During the cruise phase, obtain a full hormone panel (total testosterone, LH, FSH, haematocrit, lipids, liver enzymes) at the midpoint and end of the cruise window; use these results to confirm readiness for the next blast and to document your hormonal baseline across training years.

Warnings

Contraindications: NordiTren A is contraindicated in individuals with prostate or breast carcinoma, severe cardiovascular disease, uncontrolled hypertension, hepatic impairment, or hypersensitivity to any formulation component. Women of childbearing potential and minors must not use this product. Blast-and-cruise protocols represent a form of continuous supraphysiological androgen exposure and are not appropriate for individuals with pre-existing lipid disorders or erythrocytosis.

Side_Effects: Androgenic side effects including acne, seborrhoea, accelerated scalp hair loss in genetically predisposed individuals, and voice deepening in females may occur. Trenbolone-specific effects — including increased perspiration, restlessness, and elevated resting heart rate — are commonly reported during blast phases and should be documented as cycle-phase markers. Haematocrit elevation is a dose-dependent risk during prolonged blast windows; blood donation or therapeutic phlebotomy may be required.

Monitoring: Full bloodwork including haematocrit, lipid panel (LDL, HDL), liver enzyme profile, PSA (in males over 40), and total testosterone should be obtained before initiating a blast, at the midpoint of the blast, and at the midpoint and end of every cruise phase. Blood pressure should be self-monitored at least twice weekly during active blast periods. Kidney function markers (creatinine, eGFR) should be assessed at minimum annually in individuals running repeated multi-compound blast cycles.

PCT: Athletes pursuing complete hormonal recovery rather than a cruise-and-re-blast strategy should initiate a standard PCT protocol once trenbolone acetate has cleared, typically beginning 5–7 days after the final injection given the ester's rapid clearance. SERM-based PCT (e.g., tamoxifen, clomiphene) for 4–6 weeks is standard; gonadotropin support (hCG) used during the blast's final weeks can reduce testicular suppression depth and shorten recovery timelines.

Frequently asked questions

What is the difference between the blast phase and the cruise phase in a trenbolone cycle?: The blast phase is a defined period of elevated androgen dosing — typically 8–16 weeks — where trenbolone acetate is added to drive maximal muscle adaptation. The cruise phase that follows uses testosterone-only maintenance dosing, commonly 100–200mg per week, for 4–12 weeks. This alternation allows partial hormonal recovery and helps preserve long-term androgen receptor responsiveness across successive training years.
How does trenbolone acetate's clearance rate affect the blast-to-cruise transition?: Trenbolone acetate clears serum meaningfully faster than long-ester variants, with detectable activity dropping sharply within approximately one week of the final injection. This means athletes can transition cleanly into the cruise phase without waiting weeks for residual hormone levels to subside — a practical advantage for anyone timing blood panels or managing total androgen load during the handoff between phases.
How many weeks should the blast phase last when using NordiTren A?: Most experienced practitioners run blast phases of 8–12 weeks when trenbolone acetate is the primary anabolic compound. Shorter blasts of 6 weeks are sometimes used for targeted pre-competition peaks. The blast length should be determined in relation to the subsequent cruise duration — a commonly cited ratio is one week of cruise for every week blasted, though individual health markers and bloodwork should guide adjustments.
Why does the 150mg/ml concentration of NordiTren A matter for blast-phase injection scheduling?: At 150mg/ml, a 450mg weekly blast dose requires only 3ml of product across the injection schedule. An equivalent dose from a 100mg/ml product requires 4.5ml — a 50% increase in total injection volume per week. Across an 8-week blast, that difference accumulates to roughly 12ml, which translates to fewer large-volume draws and reduced injection-site stress during high-frequency dosing.
Can NordiTren A be drawn with an insulin syringe, and how should the vial be stored after first use?: Drawing from a 150mg/ml oil-based preparation with an insulin syringe is technically possible for very small doses but is generally impractical due to viscosity; a 23–25g needle is the standard recommendation for both drawing and injection. After first puncture, the vial should be stored upright at room temperature away from light and heat, used within the period indicated on the label, and the stopper should be swabbed with an alcohol wipe before each draw to maintain sterility. (2) angle_used

Manufacturer

Nordi Pharma's pricing and availability architecture for NordiTren A reflects a deliberate positioning decision: the 150mg/ml concentration is offered at a price point that keeps cost-per-milligram competitive relative to lower-concentration alternatives, meaning athletes running blast-phase doses of 300–450mg per week do not face a disproportionate per-cycle cost penalty for the concentration advantage. Stock availability is maintained through a regional distribution network designed to prevent the supply gaps that disrupt multi-week blast schedules — an operational consideration Nordi Pharma treats as directly relevant to user safety, since mid-blast compound substitution introduces dose and formulation variables that undermine cycle integrity. Transparent batch documentation — including HPLC potency verification and LAL endotoxin assay data — is retained per lot as part of the release record, ensuring that the declared 150mg/ml concentration is commercially reliable rather than aspirational.

Product details

Brand	Nordi Pharma
Active ingredient	trenbolone acetate
Also known as	Tren A, Trenbolone Acetate, Finaplix, NordiTren A, Nordi Pharma Tren A
Strength	150 mg
Form	Vial
Pack size	1 piece
Item number	INJ-TACE-NOR-150-015

Reviews

4.5/5

2 reviews

Rating: 5 out of 5 starsTonyVerified purchaseJul 23, 2026
tren A done right
Pinning EOD at 450mg/week total. Sweats are real, sleep took a hit around week 3 but nothing I haven't dealt with before. Strength gains were insane, up 20kg on my deadlift in 8 weeks. Vascularity through the roof. This batch is definitely dosed properly, no doubt about it
Rating: 4 out of 5 starskettlebellVerified purchaseJun 24, 2026
Quality stuff, pip first week
Pip on the first few shots was pretty uncomfortable, glutes were sore for a couple days each time. Settled down after week 1 though. running 300mg/week and the results are everything you expect from tren a, strength, hardness, aggression in the gym. Wouldn't put me off ordering again, just heads up on early pip

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Optimal Dosage

Acro-Trenbolone 100mg/ml 10ml Vial by Beligas Pharmaceuticals

Acro-Trenbolone is a sterile, oil-based intramuscular solution delivering Trenbolone Acetate at 100 mg per millilitre across a 10 ml multi-dose vial — engineered specifically to bypass hepatic first-pass catabolism and achieve near-complete systemic bioavailability that no oral anabolic compound can match. Because the active hormone enters circulation directly through intramuscular absorption rather than the gastrointestinal tract, essentially none of the injected dose is destroyed before it reaches target androgen receptors. Quality assurance at Beligas Pharmaceuticals is enforced through a layered release protocol: HPLC-verified potency, LAL endotoxin testing, and GMP-certified production conditions — each checkpoint documented before the vial leaves the facility.

€48.00

Trenbolin-100 100mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Fast Acting

Trenbolin-100 100mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Trenbolin-100 is an oil-based injectable Trenbolone Acetate formulated at 100mg/ml, engineered for rapid onset of action — making it the go-to ester choice when time-to-effect and dosing efficiency both matter. Each 1ml ampoule delivers a precise, single-use dose of one of the most potent anabolic compounds available, with the acetate ester's short chain enabling plasma concentration peaks within 24–48 hours of administration. Potency is confirmed batch-to-batch via HPLC quantification; sterility is validated through LAL endotoxin screening — both conducted under GMP-certified clean-room conditions at BM Pharmaceuticals' Indian facility.

€54.00

High Concentration

TrenaTrex 150mg/ml 10ml Vial by Concentrex Labs

TrenaTrex by Concentrex Labs delivers Trenbolone Acetate at 150 mg/ml in a 10 ml multi-dose vial, engineered for athletes who demand structured, time-anchored injection scheduling to sustain stable circulating hormone levels across every training week. The acetate ester's approximately 48-hour half-life means that consistent administration timing — not rough approximation — is the primary determinant of anabolic continuity throughout a cycle. Every batch undergoes HPLC potency quantification and LAL endotoxin testing before release, confirming both the 150 mg/ml concentration and pyrogen-free sterility.

€55.00

Brand Quality

Trenbolone 100 100mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma Trenbolone 100 is a single-ingredient injectable solution delivering Trenbolone Acetate at 100mg/ml across a 10ml multi-dose vial, specifically suited to frontloading strategies where a calculated loading dose accelerates the attainment of target blood levels from the very first injection day. Because the acetate ester carries one of the shortest half-lives among trenbolone esters (approximately 2–3 days), the gap between first injection and productive working concentration is inherently short — and a deliberate frontload compresses it further, letting athletes enter the active phase of a cycle days earlier than a flat-dose approach permits. Every batch of Trenbolone 100 passes HPLC potency verification and LAL endotoxin screening before release; lot-specific certificates confirm that declared concentration and sterility specifications are met across the full 10ml fill.

€46.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00